Dr. Li received his M.D. from Peking Union Medical College (Institute of Hematology) and Tsinghua University. He has more than ten years of experience as a hematologist and then switched his career to translational research in blood cancers. After completing his postdoctoral training at the University of Miami about myeloid malignancies and at the University of Florida about lymphoid malignancies, Dr. Li joined the NCI-designated Sidney Kimmel Comprehensive Cancer Center at Jefferson Health in November 2023. His research focuses on the roles of chromatin regulators in normal and malignant hematopoiesis, blood cancer relapse, and therapy resistance. Findings from his work include: 1) demonstration of the role of ASXL2 and ASXL1 in normal hematopoiesis and myeloid malignancies using mouse models; 2) elucidation of the aberrant epigenetic landscape underlying the mechanism of relapse of acute lymphoblastic leukemia and mantle cell lymphoma driven by NSD2 mutation using CRISPR/Cas9-edited cell lines, PDX and a novel conditional mouse model; and 3) utilizing the insight of epigenetic mechanisms and developing novel targeting therapies to overcome glucocorticoid resistance driven by NSD2 mutation. The strategy has been presented to the Children’s Oncology Group (COG) as a potential clinical trial.